Objective: This is a pharmacoeconomic evaluation of two therapy schedules using drugs with different modes of action: Degarelix and triptorelin in the treatment of patients with advanced hormone-dependent prostate cancer. Methods: We reviewed the literature on the standard treatment for these patients, early and late effects of existing therapies, and we also performed a valuation using the Comprehensive Cost Treatment EsSalud (Peruvian Social Security) rates. Results: The Comprehensive Cost Treatment is S/. 10 793 for a patient using Degarelix and S/. 12 251 for a patient using generic triptorelin, so the therapy with the GnRH antagonist generates S/. 1 458 savings per patient. Conclusions: This represents S/. 1,008,017 savings for all patients with advanced hormone-dependent prostate who attend to EsSalud, with the added advantage that there are no extra costs with ...

Objective: This is a pharmacoeconomic evaluation of two therapy schedules using drugs with different modes of action: Degarelix and triptorelin in the treatment of patients with advanced hormone-dependent prostate cancer. Methods: We reviewed the literature on the standard treatment for these patients, early and late effects of existing therapies, and we also performed a valuation using the Comprehensive Cost Treatment EsSalud (Peruvian Social Security) rates. Results: The Comprehensive Cost Treatment is S/. 10 793 for a patient using Degarelix and S/. 12 251 for a patient using generic triptorelin, so the therapy with the GnRH antagonist generates S/. 1 458 savings per patient. Conclusions: This represents S/. 1,008,017 savings for all patients with advanced hormone-dependent prostate who attend to EsSalud, with the added advantage that there are no extra costs with ...

El presente trabajo de investigación pretende definir si existe asociación entre diferentes factores clínicos y laboratoriales al debut de la enfermedad con la respuesta a la primera línea de tratamiento y sobrevida para los Linfoma No Hodgkin de Alto Grado de malignidad. Se estudiaron 327 pacientes diagnosticados de Linfoma No Hodgkin en el servicio de Oncología del Hospital Nacional Edgardo Rebagliatti Martins entre el mes de Enero de 1997 y a Diciembre del 2000. El problema planteado fue si existe asociación entre los factores pronósticos estudiados con la sobrevida global, sobrevida libre de eventos y respuesta completa al tratamiento de los pacientes con Linfoma No Hodgkin.